Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-09-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于公司向不特定对象发行可转换公司债券之补充法律意见书（一）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the issuance of convertible bonds by a company. It includes extensive legal and financial analysis related to the bond issuance, investment projects, capital expenditures, and regulatory compliance. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a legal opinion related to capital raising activities, specifically the issuance of convertible bonds. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Therefore, the classification is CAP with high confidence.
2020-09-29 Chinese
关于使用闲置自有资金购买现金理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company regarding the use of idle funds to purchase cash management financial products. It details the amounts, types of products, expected yields, risk management measures, and the impact on the company. It references prior shareholder meeting approvals and discloses specific financial transactions related to cash management. The document is relatively short (2358 characters) and serves as a disclosure of a financing activity involving the company's own funds, rather than a full financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP) as it updates on company financing activities and capital usage.
2020-09-29 Chinese
关于《关于健帆生物科技集团股份有限公司申请向不特定对象发行可转换公司债券的审核问询函》的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry from the Shenzhen Stock Exchange regarding the company's application to issue convertible bonds to unspecified investors. It includes extensive financial data, investment project details, capital expenditure breakdowns, and usage of raised funds. The content focuses on the company's capital raising activities, project investment plans, and financial data related to the issuance of convertible bonds. There is no indication that this is a full annual or interim report, audit report, or earnings release. Instead, it is an update and detailed explanation related to a capital raising and financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2020-09-29 Chinese
《关于申请向不特定对象发行可转换公司债券的审核问询函的回复》的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding its response to a regulatory inquiry about applying for the issuance of convertible bonds to unspecified investors. It references a regulatory review process by the Shenzhen Stock Exchange and the China Securities Regulatory Commission. The document does not contain financial statements or detailed financial data but rather discusses the regulatory review and the company's compliance and disclosure obligations. The document length is short (736 characters), and it serves as an announcement of regulatory correspondence and status update on a financing matter. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and regulatory approval process for bond issuance.
2020-09-29 Chinese
公司与中航证券有限公司关于申请向不特定对象发行可转换公司债券的审核问询函的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed written response to a regulatory inquiry from the Shenzhen Stock Exchange regarding the company's application to issue convertible bonds to unspecified investors. It includes extensive financial and project investment details, such as capital expenditure breakdowns, project progress, and funding usage plans. The content focuses on the company's capital raising activities and the use of proceeds from the convertible bond issuance. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. Instead, it is a regulatory filing related to capital raising and financing activities, specifically a reply to an inquiry about a convertible bond issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2020-09-29 Chinese
关于收到《关于健帆生物科技集团股份有限公司申请向不特定对象发行可转换公司债券的审核问询函》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the receipt of an inquiry letter from the Shenzhen Stock Exchange about the company's application to issue convertible bonds to unspecified investors. It discusses the review process and the need for regulatory approval before the issuance can proceed. The document is short (714 characters) and serves as a notification of regulatory review and ongoing compliance, rather than containing financial data or detailed report content. It does not present financial statements, management discussion, or detailed report data. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-09-14 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.